Active Not Recruiting PHASE1 INTERVENTIONAL 6-arm NCT03791112

A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor

Sponsor: Betta Pharmaceuticals Co., Ltd.

Interventions BPI-16350

Updated 7 times since 2019 Last updated: Jan 22, 2025 Started: Jul 18, 2019 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Solid Cancer and is currently ongoing. Betta Pharmaceuticals Co., Ltd. leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Feb 2025 — Present [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jul 2022 — Jul 2024 [monthly]

Recruiting PHASE1

Status: Unknown Status → Recruiting
Jan 2022 — Jul 2022 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status

▶ Show 2 earlier versions

Jan 2021 — Jan 2022 [monthly]

Not Yet Recruiting PHASE1
Feb 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Betta Pharmaceuticals Co., Ltd.

Data source: Betta Pharmaceuticals Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China